The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome
- PMID: 18565127
- DOI: 10.1111/j.1742-1241.2008.01825.x
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome
Abstract
Context: The prevalence of non-alcoholic fatty liver disease (NAFLD) in polycystic ovarian syndrome (PCOS) is high. Small studies have shown reductions in serum alanine aminotransaminase (ALT) and gamma-glutamyltransaminase (GGT) concentrations, both surrogate liver fat markers, and sometimes improvements in liver histology in individuals with NAFLD treated with metformin.
Aims: We investigated whether metformin reduces serum ALT and GGT concentrations in obese women with PCOS.
Methods: We performed post hoc data analysis from a trial, involving 82 obese women aged 22-46 years with PCOS, conducted at an academic institution. Participants were treated with metformin 1500 or 2550 mg/day for 8 months. Anthropometric measurements and blood samples (serum ALT, GGT, lipids, leptin, C-reactive protein, insulin, glucose analyses) were taken at baseline, 4 and 8 months.
Results: Sixty-six participants completed the study. Mean weight, serum ALT and GGT decreased from 100.3 to 96.6 kg (p < 0.0001), 29.7 to 25.8 U/l (p = 0.012) and 21.4 to 16.9 U/l (p < 0.0001) respectively. Associations between weight reduction and decreases in serum ALT and GGT were highly significant and independent of change in Homeostasis Model Assessment of Insulin Resistance. In women with baseline ALT > 29.7 U/l (median), ALT reduction was highly significant (p = 0.005); however in those with baseline ALT < 29.7 U/l, ALT did not change despite similar weight reduction. There was no difference in reductions in ALT and GGT when the two metformin doses were compared. Intention-to-treat analyses gave comparable results.
Conclusions: Metformin therapy is associated with reductions in surrogate liver fat markers in obese women with PCOS. This adds indirect support for a benefit of metformin in attenuating/reversing liver fat accumulation in PCOS and more generally.
Similar articles
-
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.Hum Reprod. 2007 Nov;22(11):2967-73. doi: 10.1093/humrep/dem271. Epub 2007 Aug 31. Hum Reprod. 2007. PMID: 17766923 Clinical Trial.
-
Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.Int J Obes (Lond). 2010 May;34(5):899-907. doi: 10.1038/ijo.2010.4. Epub 2010 Feb 9. Int J Obes (Lond). 2010. PMID: 20142825
-
Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.Clin Endocrinol (Oxf). 2008 Oct;69(4):562-7. doi: 10.1111/j.1365-2265.2008.03204.x. Epub 2008 Jan 31. Clin Endocrinol (Oxf). 2008. PMID: 18248643 Clinical Trial.
-
Use of metformin in polycystic ovary syndrome.Am J Obstet Gynecol. 2008 Dec;199(6):596-609. doi: 10.1016/j.ajog.2008.09.010. Am J Obstet Gynecol. 2008. PMID: 19084097 Review.
-
Role of obesity and adiposity in polycystic ovary syndrome.Int J Obes (Lond). 2007 Nov;31 Suppl 2:S8-13; discussion S31-2. doi: 10.1038/sj.ijo.0803730. Int J Obes (Lond). 2007. PMID: 17968437 Review.
Cited by
-
Organokines and liver enzymes in adolescent girls with polycystic ovary syndrome during randomized treatments.Front Endocrinol (Lausanne). 2024 May 16;15:1325230. doi: 10.3389/fendo.2024.1325230. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38818508 Free PMC article. Clinical Trial.
-
Metformin and the Liver: Unlocking the Full Therapeutic Potential.Metabolites. 2024 Mar 25;14(4):186. doi: 10.3390/metabo14040186. Metabolites. 2024. PMID: 38668314 Free PMC article. Review.
-
Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s.Biomedicines. 2024 Mar 14;12(3):653. doi: 10.3390/biomedicines12030653. Biomedicines. 2024. PMID: 38540265 Free PMC article. Review.
-
Metformin Improves the Hepatic Steatosis Index in Non-Obese Patients with Polycystic Ovary Syndrome.J Clin Med. 2022 Jul 24;11(15):4294. doi: 10.3390/jcm11154294. J Clin Med. 2022. PMID: 35893386 Free PMC article.
-
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome.Diabetes Metab Syndr Obes. 2022 Apr 24;15:1281-1291. doi: 10.2147/DMSO.S362424. eCollection 2022. Diabetes Metab Syndr Obes. 2022. PMID: 35494531 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous